DoseCare has acquired Biodose, a monitored dosage system (MDS) that accommodates liquid and solid medication.
The company has assured there will be no disruption to services to pharmacies and care home suppliers, and no planned increase in prices.
Biodose is a medication management solution that is used in the pharmacy and care home sectors to manage complex medication regimes, with the aims of increasing efficiency and improving patient safety.
DoseCare has acquired the intellectual property rights to enable manufacture of the trays, pods and seals in the future. It has also acquired all current stock, from Protomed Ltd (T/A Biodose), which ceased trading in October to November.
Biodose is a system that allows the pre-measured, personalised dosage of tablets, capsules and liquids. Medication is stored in individual tamper-evident sealed units, pods, that include information including patient name, description of medicines contained inside, as well as a date and time that the medication should be taken.
Donna Williams from DoseCare said: “Having worked with Biodose from a pharmacy and care home perspective, the team here understand the immense value that Biodose provides to both these sectors; we feel this acquisition provides a unique opportunity to not only ensure continuity but also drive the future strategy of the most superior MDS solution in the healthcare market. We look forward to working closely with, and supporting, valued Biodose customers to deliver greater improvements and cost-efficiencies.”
